Managing Bone Health in Metastatic Breast Cancer
0 Views
administrator
07/03/23
Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).
To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge
-
Category
Show more
Facebook Comments
No comments found